Gilead Sciences Clinical Trial Pipeline — 104 Active Studies

Phase 1: 24, Phase 2: 36, Phase 3: 36, Other: 8

Gilead Sciences has evolved from a virology-focused company into a diversified biopharmaceutical with major oncology and liver disease programs. Their hematology-oncology franchise centers on CAR-T therapies — Yescarta (axicabtagene ciloleucel) for large B-cell lymphoma and follicular lymphoma, and Tecartus (brexucabtagene autoleucel) for mantle cell lymphoma and B-cell ALL. Through the acquisition of Immunomedics, Gilead gained Trodelvy (sacituzumab govitecan), a TROP2-targeting ADC approved in triple-negative breast cancer and urothelial cancer, with an active expansion program in HR+ breast cancer, NSCLC, and other solid tumors. In liver disease, Gilead's NASH/MASH pipeline includes seladelpar (PPARδ), cilofexor, and firsocostat across multiple combination trials. Their HIV franchise — anchored by Biktarvy and the lenacapavir long-acting program — continues generating registrations for pre-exposure prophylaxis and treatment extensions.

• Hematology / oncology (CAR-T, ADC)
• Solid tumors (TROP2, TROP2 combos)
• HIV (long-acting, PrEP, treatment)
• Liver disease (NASH/MASH, HCV/HBV)
• Inflammation (filgotinib, JAK1)

• Yescarta (axicabtagene ciloleucel) — CD19 CAR-T, LBCL/FL
• Trodelvy (sacituzumab govitecan) — TROP2 ADC, TNBC/urothelial
• Tecartus (brexucabtagene autoleucel) — CD19 CAR-T, MCL/B-ALL
• Lenacapavir — HIV capsid inhibitor, long-acting
• Seladelpar — PPARδ agonist, MASH/PBC
• Magrolimab — CD47 antibody, myeloid malignancies

Gilead's Trodelvy (sacituzumab govitecan) expansion trials — into HR+ breast cancer, NSCLC, and endometrial cancer — are among the most competitive in the TROP2 ADC space, directly competing with AstraZeneca's Dato-DXd. Their lenacapavir long-acting HIV program is closely tracked for its pre-exposure prophylaxis indication registrations.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Gilead Sciences's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.

• Sponsor normalization: Gilead Sciences may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.